Citigroup Raises Establishment Labs (NASDAQ:ESTA) Price Target to $47.00

Establishment Labs (NASDAQ:ESTA - Free Report) had its price objective lifted by Citigroup from $38.00 to $47.00 in a report issued on Wednesday,Benzinga reports. The firm currently has a neutral rating on the stock.

Several other research analysts have also commented on the stock. Needham & Company LLC restated a "buy" rating and set a $48.00 price target on shares of Establishment Labs in a research note on Friday, June 13th. Wall Street Zen upgraded shares of Establishment Labs from a "sell" rating to a "hold" rating in a research note on Saturday, June 14th. Finally, BTIG Research began coverage on shares of Establishment Labs in a research note on Friday, May 16th. They set a "buy" rating and a $62.00 price target on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $51.80.

Establishment Labs Trading Down 2.3%

Establishment Labs stock traded down $1.08 during trading hours on Wednesday, hitting $44.89. The company had a trading volume of 192,033 shares, compared to its average volume of 479,416. The company has a quick ratio of 2.05, a current ratio of 3.36 and a debt-to-equity ratio of 5.72. The firm's fifty day moving average is $38.21 and its 200-day moving average is $36.92. Establishment Labs has a fifty-two week low of $26.56 and a fifty-two week high of $52.41.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.83) by $0.13. The firm had revenue of $41.38 million for the quarter, compared to analyst estimates of $41.15 million. Establishment Labs had a negative net margin of 52.34% and a negative return on equity of 196.25%. The company's revenue for the quarter was up 11.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.58) EPS. Research analysts anticipate that Establishment Labs will post -2.41 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Elevation Point Wealth Partners LLC acquired a new position in Establishment Labs in the 1st quarter valued at $207,000. Raymond James Financial Inc. acquired a new position in Establishment Labs in the 4th quarter valued at $5,494,000. Northern Trust Corp grew its stake in Establishment Labs by 53.9% in the 4th quarter. Northern Trust Corp now owns 28,165 shares of the company's stock valued at $1,298,000 after buying an additional 9,865 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new position in Establishment Labs in the 4th quarter valued at $161,000. Finally, Swiss National Bank grew its stake in Establishment Labs by 2.7% in the 4th quarter. Swiss National Bank now owns 38,500 shares of the company's stock valued at $1,774,000 after buying an additional 1,000 shares during the last quarter. 72.91% of the stock is currently owned by institutional investors and hedge funds.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.